Time to Ban Nimesulide From the Libyan Medicines Market

Amal Y Benkorah; Manal Hadood; Aisha Rafaei; Ghazi Benkura

doi:10.54361/ljmr.v14i1.07

Authors

Amal Y Benkorah Faculty of Pharmacy, University of Tripoli, Tripoli, Libya Author
Manal Hadood Faculty of Pharmacy, University of Tripoli, Tripoli, Libya Author
Aisha Rafaei Faculty of Pharmacy, University of Tripoli, Tripoli, Libya Author
Ghazi Benkura Faculty of Dentistry, University of Zawia, Zawia, Libya Author

DOI:

https://doi.org/10.54361/ljmr.v14i1.07

Keywords:

Nimesulide, adverse drug reaction, drug-induced liver injury, ban, Libya

Abstract

Nimesulide is a non-steroidal anti-inflammatory drug with analgesic and antipyretic properties which was launched in Italy as Aulin® in 1985. Huge concerns were raised regarding this drug as its users are at a high risk for developing a serious ADR called Drug-Induced liver Injury which may lead to liver failure. The goal of this study was to sheds light on nimesulide which is present illegally in private pharmacies and to the harm that it may pose on public health; in order to draw the attention of the responsible authorities to the danger of its availability in our market. A survey of 65 pharmacies in Tripoli was conducted to identify the availability of nimesulide in these pharmacies. The knowledge of its different dosage forms, strength, brands available, pattern of prescribing, and ADRs among pharmacists and coworkers were all collected. 100 % response was obtained as 65 pharmacy personnel answered the questionnaire. We found out that this medicine is available in all of them. The response to the questionnaire is illustrated in figures from1 to 4. Nimesulide dispensing pattern was shown to be almost always through patients’ request. In conclusion, the uncontrolled presence of this medicine may pose a public health risk, therefore a request for its ban from Libyan market should be seriously considered

References

Rainsford KD, Bevilacqua M, Dallegri F, et al. (2005) Pharmacological properties of nimesulide. In: Nimesulide - Actions and Uses. pp. 133-244. (Birkhauser Verlag AG). DOI: https://doi.org/10.1007/3-7643-7410-1_4

Nimesulide. https://www.drugbank.ca/drugs/DB04743. Accessed October 18, 2018.

Ostapowicz G, Fontana RJ, Schioødt F V., et al. (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 137 (12): 947-954. DOI: https://doi.org/10.7326/0003-4819-137-12-200212170-00007

Reuben A, Koch DG, Lee WM (2010) Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatol. 52(6): 2056-2076. DOI: https://doi.org/10.1002/hep.23937

Wei G, Bergquist A, Broomé U, et al. (2007) Acute liver failure in Sweden: Etiology and outcome. J Intern Med. 262(3): 393-401. DOI: https://doi.org/10.1111/j.1365-2796.2007.01818.x

Bechmann LP, Manka P, Best J, et al. (2014) Drug-induced liver injury as predominant cause of acute liver failure in a monocenter study. Dtsch Med Wochenschr. 139(17): 878-882. DOI: https://doi.org/10.1055/s-0034-1369932

Watkins PB, Seeff LB (2006) Drug-induced liver injury: summary of a single topic clinical research conference. Hepatol. 43(3): 618-31. DOI: https://doi.org/10.1002/hep.21095

Navarro VJ, Senior JR. (2006) Drug-Related Hepatotoxicity. N Engl J Med. 354(7): 731-739. DOI: https://doi.org/10.1056/NEJMra052270

Abboud G, Kaplowitz N. (2007) Drug-induced liver injury. Drug Safety. 30(4): 277-294. DOI: https://doi.org/10.2165/00002018-200730040-00001

Day RO, Graham GG. (2013) Non-steroidal anti-inflammatory drugs (NSAIDs). Br J Sports Med. 47(17):1127. DOI: https://doi.org/10.1136/bjsports-2013-f3195rep

Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. (2015) Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. (4): 285-91. DOI: https://doi.org/10.1016/j.ejim.2015.03.008

Motola D, Vargiu A, Leone R, et al. (2007) Hepatic adverse drug reactions: A case/non-case study in Italy. Eur J Clin Pharmacol. 63(1): 73-79. DOI: https://doi.org/10.1007/s00228-006-0222-z

Nimesulide | European Medicines Agency. https://www.ema.europa.eu/medicines/human /referrals /nimesulide-1. Accessed October 18, 2018.

The International Society of Drug Bulletins - Nimesulide must be withdrawn worldwide due to serious liver damage. Therapeutics Initiative. https://www.ti.ubc.ca/2008/02/04/nimesulide-must-be-withdrawn-worldwide-due-serious-liver-damage/. Accessed October 21, 2018.